Current procedures for the treatment of metastatic pancreatic cancer


MUDr. Petr Karásek

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno



Pancreatic cancer is a highly aggressive malignancy with poor treatment results at all stages. At the time of diagnosis, metastatic spread or locally advanced disease is present in most patients. Despite low efficacy, gemcitabine monotherapy has been used in palliative treatment of advanced disease for many years. In recent years therapeutic options have expanded significantly. In palliative treatment of the first line, FOLFIRINOX and nab-paclitaxel/ gemcitabine regimens have been introduced into clinical routine, which increased the overall survival by 4-5 months. Other possibilities prolongation of survival is the second line treatment with nanoliposomal irinotecan in combination with 5-fluorouracil and leucovorin in patients pretreated with gemcitabine regimen. Interesting results brings the studies aimed at influencing the extracellular matrix of tumor cells.



pancreatic cancer, chemotherapy, palliation



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...